Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares dropped 2.5% on Monday . The company traded as low as $4.79 and last traded at $4.75. Approximately 3,127 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 15,404 shares. The stock had previously closed at $4.87.
Analyst Ratings Changes
Separately, Guggenheim lowered their price objective on shares of Nanobiotix from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday, April 4th.
View Our Latest Stock Analysis on NBTX
Nanobiotix Stock Up 0.8%
The stock's fifty day moving average price is $4.33 and its two-hundred day moving average price is $3.70.
Institutional Investors Weigh In On Nanobiotix
A number of hedge funds have recently made changes to their positions in NBTX. Geode Capital Management LLC bought a new stake in Nanobiotix during the 4th quarter valued at $29,000. Millennium Management LLC bought a new stake in Nanobiotix during the 4th quarter valued at $39,000. Jane Street Group LLC bought a new stake in Nanobiotix during the 4th quarter valued at $73,000. Finally, OLD Mission Capital LLC bought a new stake in Nanobiotix during the 4th quarter valued at $139,000. 38.81% of the stock is currently owned by institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
